Description of Renal Involvement in Wilson's Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age7+
SponsorFondation Ophtalmologique Adolphe de Rothschild

About this trial

Wilson's disease (WD) is a rare genetic disorder that leads to copper accumulation in various tissues, including the liver, nervous system, heart, and kidneys. Renal involvement in WD has been poorly studied, and systematic screening is not currently recommended.

Indirect renal complications are the most common, such as hepatorenal and cardiorenal syndromes, as well as severe complications like hemolysis or rhabdomyolysis. However, literature suggests that copper may exert a direct toxic effect on renal tubular cells, leading to both proximal and distal tubular dysfunction. These may manifest through often subtle signs, such as aminoaciduria, glycosuria, hypouricemia, and low-molecular-weight proteinuria. Electrolyte imbalances of varying severity may also occur, including hypokalemia, which can cause muscle cramps and cardiac arrhythmias, as well as acid-base disorders (proximal or distal renal tubular acidosis), and/or phosphate-calcium metabolism abnormalities (phosphate diabetes and hypercalciuria). These latter issues may lead to complications such as urinary stones, nephrocalcinosis, and even fracture-related osteoporosis.

In addition, long-term treatment with D-penicillamine (DPA), a common therapy for WD, can cause renal damage in 10-20% of cases, mainly affecting the glomeruli. This includes membranous nephropathy, severe proliferative glomerulonephritis, or nephrotic syndrome with minimal change disease.

Without appropriate monitoring and preventive care, both direct and indirect renal complications can lead to acute or chronic kidney failure. It is likely that the prevalence and systemic impact of renal involvement in WD are currently underestimated.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient aged 7 years and older

Diagnosed with Wilson's disease, with a Leipzig score ≥ 4

Disqualifiers

Patient who has undergone organ transplantation

Known renal comorbidity unrelated to Wilson's disease

Pregnant or breastfeeding woman

Trial population

Patients followed for Wilson disease accepting to undergo full renal workup (biology and echography)

Trial design

Design model

Case-only

Time perspective

Cross-sectional

Treatments tested in this trial

  • full renal workup

    Other intervention

    full renal workup (biology and echography)

Treatment groups

150 Participants
are divided into 1 treatment group
Group A: Wilson disease patients1 intervention

Trial outcomes

Primary outcomes

1

Prevalence of renal involvement in Wilson's disease

Renal involvement is defined by the presence of at least one of the following criteria: * Chronic kidney disease, defined by an estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m² and/or proteinuria \> 0.5 g/g of creatinine. * Markers of proximal tubulopathy, defined by at least one of the following: phosphate diabetes (renal phosphate wasting), hypokalemia, normoglycemic glycosuria, β2-microglobulinuria, hypouricemia, or metabolic acidosis. * Hypercalciuria and/or urolithiasis.

Time frame
Day 0

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.